Browse the evidence

People in Northern China often consume more plant-based foods.

Understanding local dietary habits can inform nutritional guidance and interventions.

Barriers to treatment for obesity-related hypertension include obesity stigma, limited access to healthcare, and adherence problems.

Addressing stigma and improving access to care are crucial for effective management of obesity-related hypertension.

The prevalence of obesity has increased four-fold over the four preceding decades, with concomitantly rising rates of hypertension.

Healthcare providers should be aware of the significant rise in obesity and hypertension prevalence.

Sub-chronic administration of 0839 and 0833 reduced food intake and body weight in DIO mice and rats.

These compounds may help in managing weight in populations with diet-induced obesity.

No significant differences in efficacy and safety of the drugs were found between age groups.

Efficacy and safety of these drugs appear consistent, regardless of age.

Rates of obesity are projected to continue to increase, with severe obesity expected to be the most common body mass index category for women in the coming decade.

Practitioners should be aware of the increasing prevalence of obesity among women and its implications for health.

Adverse effects of tirzepatide are most often mild and well tolerated, with no significant impact on patients’ quality of life.

Tirzepatide may be a safe option for patients concerned about side effects.

Obesity treatment could generate a social return on investment of $3.81 per dollar nationally and $8.57 from states’ perspective.

Investing in obesity treatment can yield significant economic returns for states and the nation.

Obesity interventions generate substantial social value totaling $15 billion in net social value nationally.

Investing in obesity treatment can lead to significant societal benefits and economic value.

36.7% of adults with obesity but without diabetes had a prescription for semaglutide or tirzepatide that lasted less than 32 days.

Practitioners should be aware that a significant portion of patients may not adhere to GLP-1 RA prescriptions.

Persistent prescriptions (coverage for ≥336 days) were observed in 18.6% of participants.

A minority of patients may maintain long-term use of GLP-1 RAs, indicating potential for sustained treatment benefits.

The oleogel-in-oleogel system is capable of delivering fewer calories than fats and most oleogels while still providing essential fatty acids.

This could be a viable alternative for those looking to reduce caloric intake from fats.

Die aktuelle private Finanzierung von GLP-1-Rezeptoragonisten schränkt den Zugang für Menschen mit niedrigem sozioökonomischem Status ein.

Praktiker sollten die finanziellen Barrieren für den Zugang zu GLP-1-Rezeptoragonisten berücksichtigen.

Es gibt ethische Bedenken bezüglich der Verschiebung von Priorisierungen hin zu einer pharmakologischen Behandlung.

Praktiker sollten die ethischen Implikationen der Verschiebung hin zu pharmakologischen Behandlungen bedenken.

Future clinical trials are needed to clarify the mechanisms of benefit and define the role of weight-reduction therapies in obesity-related HFpEF.

Clinicians should be aware that ongoing research may further inform treatment strategies for obesity-related HFpEF.

Among patients who discontinued treatment, 72% did not demonstrate weight regain.

Clinicians may find that many patients can maintain weight after stopping GLP-1RA therapy.

Unerwünschte Wirkungen von Semaglutid sind gut dokumentiert, insbesondere gastrointestinale Beschwerden.

Ärzte sollten über die häufigsten Nebenwirkungen von Semaglutid informiert sein, um Patienten entsprechend zu beraten.

28.1% of eligible patients were current users of GLP-1 receptor agonists.

A notable proportion of eligible OSA patients are utilizing GLP-1 RAs, indicating potential treatment pathways.

Having Medicaid was associated with a lower likelihood of using GLP-1 receptor agonists among eligible patients.

Practitioners should be aware that socioeconomic factors, such as Medicaid coverage, may influence GLP-1 RA utilization.

There was no significant effect of whey or soy protein supplementation on lean body mass (LBM) or squat performance.

Practitioners should note that whey and soy protein may not significantly impact LBM or squat performance.

There is significant heterogeneity in the theoretical models and psychometric properties of existing tools assessing DEAB in athletes.

Practitioners should be cautious when interpreting results from various DEAB assessment tools due to their differing foundations and properties.

Resistance training frequency does not significantly affect changes in muscle mass.

Increasing resistance training frequency may not lead to greater muscle mass gains.

Supplementation often fails to improve protein balance or related physiological and performance outcomes under severe operational stress.

Practitioners should consider that protein supplementation may not be beneficial in high-stress operational environments.

Pre-intervention, the score of the survey of adherence to the Mediterranean diet was relatively low (7.44 ± 0.22 points).

Understanding baseline adherence levels can help tailor interventions effectively.